RETMEN2A and RETMEN2B oncoproteins are targets of PP1 inhibitor

Italia Bongarzone; Cristiana Carniti; Carla Perego; Piera Mondellini; Marco Alessandro Pierotti

RETMEN2A and RETMEN2B oncoproteins are targets of PP1 inhibitor

Italia Bongarzone, Cristiana Carniti, Carla Perego, Piera Mondellini, Marco Alessandro Pierotti

Fondazione IRCCS Istituto Nazionale dei Tumori

Research output: Contribution to journal › Article › peer-review

Abstract

Medullary thyroid carcinoma (MTC) responds very poorly to chemotherapy. Mutations in the RET gene are critical for MTC pathogenesis. RET therefore represents a rational target for the development of novel MTC therapies. The accumulation of evidence from laboratory studies strongly suggests that PP1 inhibitor is a cytostatic agent for cells expressing RET oncoproteins. PP1 functions as a potent and selective inhibitor of RET oncoprotein phosphorylation, promoting its proteasomal degradation.

Original language	English
Pages (from-to)	550-552
Number of pages	3
Journal	Tumori
Volume	89
Issue number	5
Publication status	Published - Sep 2003

Keywords

Medullary thyroid cancer pathogenesis
MEN 2A
MEN 2B
PP1 inhibitor
RET oncoproteins

ASJC Scopus subject areas

Cancer Research

Access to Document

Fingerprint Dive into the research topics of 'RETMEN2A and RETMEN2B oncoproteins are targets of PP1 inhibitor'. Together they form a unique fingerprint.

Cite this

@article{610d8eaccb5f4803ac29ea192022dfaf,

title = "RETMEN2A and RETMEN2B oncoproteins are targets of PP1 inhibitor",

abstract = "Medullary thyroid carcinoma (MTC) responds very poorly to chemotherapy. Mutations in the RET gene are critical for MTC pathogenesis. RET therefore represents a rational target for the development of novel MTC therapies. The accumulation of evidence from laboratory studies strongly suggests that PP1 inhibitor is a cytostatic agent for cells expressing RET oncoproteins. PP1 functions as a potent and selective inhibitor of RET oncoprotein phosphorylation, promoting its proteasomal degradation.",

keywords = "Medullary thyroid cancer pathogenesis, MEN 2A, MEN 2B, PP1 inhibitor, RET oncoproteins",

author = "Italia Bongarzone and Cristiana Carniti and Carla Perego and Piera Mondellini and Pierotti, {Marco Alessandro}",

year = "2003",

month = sep,

language = "English",

volume = "89",

pages = "550--552",

journal = "Tumori",

issn = "0300-8916",

publisher = "SAGE Publications Ltd",

number = "5",

}

TY - JOUR

T1 - RETMEN2A and RETMEN2B oncoproteins are targets of PP1 inhibitor

AU - Bongarzone, Italia

AU - Carniti, Cristiana

AU - Perego, Carla

AU - Mondellini, Piera

AU - Pierotti, Marco Alessandro

PY - 2003/9

Y1 - 2003/9

N2 - Medullary thyroid carcinoma (MTC) responds very poorly to chemotherapy. Mutations in the RET gene are critical for MTC pathogenesis. RET therefore represents a rational target for the development of novel MTC therapies. The accumulation of evidence from laboratory studies strongly suggests that PP1 inhibitor is a cytostatic agent for cells expressing RET oncoproteins. PP1 functions as a potent and selective inhibitor of RET oncoprotein phosphorylation, promoting its proteasomal degradation.

AB - Medullary thyroid carcinoma (MTC) responds very poorly to chemotherapy. Mutations in the RET gene are critical for MTC pathogenesis. RET therefore represents a rational target for the development of novel MTC therapies. The accumulation of evidence from laboratory studies strongly suggests that PP1 inhibitor is a cytostatic agent for cells expressing RET oncoproteins. PP1 functions as a potent and selective inhibitor of RET oncoprotein phosphorylation, promoting its proteasomal degradation.

KW - Medullary thyroid cancer pathogenesis

KW - MEN 2A

KW - MEN 2B

KW - PP1 inhibitor

KW - RET oncoproteins

UR - http://www.scopus.com/inward/record.url?scp=0347194145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347194145&partnerID=8YFLogxK

M3 - Article

C2 - 14870784

AN - SCOPUS:0347194145

VL - 89

SP - 550

EP - 552

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 5

ER -